ArticleNeuro-oncology2012
Relative survival of patients with supratentorial low-grade gliomas.
Article in Neuro-oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis.Frontiers in neurology · 2020Pooled it
- Arterial spin labeling MR imaging for differentiation between high- and low-grade glioma-a meta-analysis.Neuro-oncology · 2018Pooled it
- Trial
- Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.Journal of neuro-oncology · 2013Trial
- Age-related risk factors and treatment outcomes in geriatric patients with spinal low-grade glioma: A nationwide analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Association of multiple trace metals in scalp hair with glioma risk: the mediating role of inflammation.Annals of clinical and translational neurology · 2024Article
- Decreased SPTBN2 expression regulated by the ceRNA network is associated with poor prognosis and immune infiltration in low‑grade glioma.Experimental and therapeutic medicine · 2023Article
- Article
- Identification of necroptosis-related genes as prognostic indicators for lower-grade glioma.American journal of cancer research · 2023Article
- Identification of efferocytosis-related subtypes in gliomas and elucidating their characteristics and clinical significance.Frontiers in cell and developmental biology · 2023Article
- Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma.iScience · 2022Article
- Exploring the relationship between age and prognosis in glioma: rethinking current age stratification.BMC neurology · 2022Article
- EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.Signal transduction and targeted therapy · 2022Article
- A prognostic pyroptosis-related LncRNA classifier associated with the immune landscape and therapy efficacy in glioma.Frontiers in genetics · 2022Article
- Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses.BioMed research international · 2022Article
- Cuproptosis-related gene signature stratifies lower-grade glioma patients and predicts immune characteristics.Frontiers in genetics · 2022Article
- CD74 Correlated With Malignancies and Immune Microenvironment in Gliomas.Frontiers in molecular biosciences · 2021Article
- Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.Frontiers in immunology · 2021Article
- Article
- Downregulation of CyclophilinA/CD147 Axis Induces Cell Apoptosis and Inhibits Glioma Aggressiveness.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to assess the population-based estimates of age-standardized survival among patients with low-grade gliomas (LGG) and to determine the impact of age and time on relative survival (RS). Data from the Surveillance, Epidemiology, and End Results (SEER) program of NCI from 1973 through 2006 were analyzed to assess survival among 5037 patients. Relationships were modeled using Dickman's piecewise constant hazards RS model. The 3- and 10-year age-standardized RS were 67% and 37%, respectively. When analyzed by age group, the 10-year overall survival (OS) and RS for children (age, <16 years), young adults (age, 16-39 years), adults (age, 40-64 years), and older patients (age, ≥65 years) were 86% and 86%, 61% and 62%, 40% and 43%, and 10% and 14%, respectively. The observed difference between OS and RS was larger among older patients (4%) and smallest among children (<1%). Older patients were 30.5 times (excess hazard ratio [eHR]; 95% confidence interval [CI], 20.3-50.0) as likely as young adults to die during the first year and 18.2 times as likely to die during the second year. Adults were 5.3 (eHR; 95% CI, 3.5-8.1) times as likely to die during their first year as young adults. In the remaining years, the observed survival differences were substantially decreased, and the presence of an age-by-follow-up interaction was observed. Survival among older patients with LGG was substantially different from the one computed for young adults and children. Despite the hazards across age groups not being proportional, RS does not provide additional information, compared with OS, in patients with LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.